IDH1 Inhibitor 5

Cat. No.:	HY-143306
CAS No.:	1940128-37-9
Molecular Formula:	$C_{26}H_{34}N_4O_3$
Molecular Weight:	450.57
Target:	Isocitrate Dehydrogenase (IDH)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	IDH1 Inhibitor 5 (compound 2) is an IDH1 (isocitrate dehydrogenase 1) inhibitor. IDH1 Inhibitor 5 inhibits MOG cells and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein with IC_{50}s of 64.4 and 34.9 nM, respectively[1].
IC_{50} & Target	IC50: 64.4 nM (MOG cells), 34.9 nM (wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein)[1]
In Vitro	IDH1 Inhibitor 5 (0-10 μM; 1 h) shows cellular potency in MOG cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay[1]

Cell Line:	MOG cell line and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein
Concentration:	0-10 μM
Incubation Time:	1 hour
Result:	Showed cellular potency to MOG cells and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein with IC_{50}s of 64.4 and 34.9 nM, respectively.

REFERENCES

[1]. Huang C, et al. Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. ACS Med Chem Lett. 2022 Mar 28;13(4):734-741.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA